ArcticZymes Technologies ASA B4V
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- NOK 1.47
- Day Range
- NOK 1.46–1.48
- 52-Week Range
- —–10.99
- Bid/Ask
- NOK 0.00 / NOK 0.00
- Market Cap
- NOK 75.59 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- 43.21
- Price/Sales
- 7.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Germany, Italy, France, and other countries.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 68
- Website
- https://www.arcticzymes.com
Comparables
Valuation
|
Metric
|
B4V
|
301207
|
300149
|
|---|---|---|---|
Price/Earnings (Normalized) | 43.21 | 14.58 | — |
Price/Book Value | 2.83 | 1.72 | 2.11 |
Price/Sales | 7.67 | 4.43 | 2.68 |
Price/Cash Flow | 30.74 | 10.76 | 21.83 |
Price/Earnings
B4V
301207
300149
Financial Strength
|
Metric
|
B4V
|
301207
|
300149
|
|---|---|---|---|
Quick Ratio | 16.79 | 2.85 | 1.46 |
Current Ratio | 18.03 | 3.42 | 1.71 |
Interest Coverage | 23.43 | 149.96 | −32.05 |
Quick Ratio
B4V
301207
300149
Profitability
|
Metric
|
B4V
|
301207
|
300149
|
|---|---|---|---|
Return on Assets (Normalized) | 5.35% | 9.24% | −34.73% |
Return on Equity (Normalized) | 5.83% | 11.52% | −54.47% |
Return on Invested Capital (Normalized) | 3.73% | 10.82% | −38.80% |
Return on Assets
B4V
301207
300149
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qtzshzznt | Prkxd | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qdfbljj | Bkmlc | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Llxjtnjfk | Vjzkmkn | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bzjrwjk | Ftfmqx | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Ddylrfxf | Lxqjx | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Nrnvnjxdm | Dvmr | $28.0 Bil | |||
| Moderna Inc
MRNA
| Mlbssqww | Hlx | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Lljdybxg | Ybcn | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wytfbfvp | Tsmfqy | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Bmhbnfbzq | Hdpzkkg | $12.6 Bil |
United States